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Summary 
Heparan sulfate proteoglycans on immune cells have the ability to bind to and 
regulate the bioactivity more than 400 bioactive protein ligands, including many 
chemokines, cytokines and growth factors. This makes them important regulators of 
the phenotype and behaviour of immune cells. Here we review how heparan sulfate 
biosynthesis in macrophages is regulated during polarization and in chronic 
inflammatory diseases such as rheumatoid arthritis, atherosclerosis, asthma, chronic 
obstructive pulmonary disease and obesity, by analyzing published micro-array data 
and mechanistic studies in this area. We describe that macrophage expression of 
many HS biosynthesis and core proteins is strongly regulated by macrophage 
polarization, and that these expression patterns are recapitulated in chronic 
inflammation. Such changes in HS biosynthetic enzyme expression are likely to have 
a significant impact on the phenotype of macrophages in chronic inflammatory 
diseases by altering their interactions with chemokines, cytokines and growth factors. 
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Macrophages perpetuate chronic inflammation  
Inflammatory responses are essential for combatting infection and promoting tissue 
repair, and are normally quickly resolved. During chronic inflammation, unchecked 
inflammation persists for months to years and can contribute to the development of 
various diseases, such as rheumatoid arthritis (RA), cardiovascular disease and 
diabetes. Incidence of many chronic inflammatory diseases is on the rise, increasing 
the need to understand the molecular events that initiate and drive disease 
pathogenesis, in order to identify novel targets for intervention.  For example, 
rheumatoid arthritis (RA) is a chronic inflammatory disease in which joint 
inflammation causes pain and loss of joint function. RA affects approximately 1% of 
the population, and while its treatment was revolutionised in the 1990s by 
development of anti-tumor necrosis factor (TNF)-targeted biologic therapies1, 30-40% 
of patients exhibit only partial or temporary responses to treatment2. Novel 
approaches are thus required to improve treatment of RA and other chronic 
inflammatory conditions.  
Chronic inflammatory conditions such as RA are characterised by elevated 
levels of pro-inflammatory cytokines (e. g. TNF, IL-1) and influx of many immune cell 
types into affected tissues3. Macrophages are a critical component of this elevated 
inflammatory response, and in RA, macrophage abundance in tissue correlates with 
joint erosion4. Macrophages respond to stimuli (such as danger signals) in their 
environment by adopting a range of activation signatures that define and regulate 
their biological responses. In vitro, two extreme activation signatures (also known as 
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polarisation states) are defined: namely, classically activated (pro-inflammatory; 
previously known as “M1”) and alternatively activated (reparative; previously known 
as “M2”) macrophages (Fig. 1A). Interferon-γ (IFNγ) and lipopolysaccharide (LPS) 
promote M1 polarisation and the expression of pro-inflammatory cytokines (e.g. IL-1, 
IL-6 and TNF), whereas IL-4 and IL-13 result in M2 polarisation and the secretion of 
anti-inflammatory cytokines like IL-10. In vivo, macrophages are thought to adopt a 
range of activation states between these two extremes, fine-tuned by their local 
environment5,6. 
In active RA, as in many other chronic inflammatory diseases, macrophages 
are thought to adopt a persistently activated state, resembling an M1 signature, 
associated with secretion of pro-inflammatory cytokines (e.g. TNF, IL-6, IL-12 and IL-
23)7. In several other chronic inflammatory conditions, a similar M1 signature has 
been demonstrated in macrophages isolated from affected tissues8. For example, 
macrophages from patients with atherosclerosis8 and obesity8 also exhibit an M1-like 
activation signature. Certain other chronic inflammatory conditions, such as asthma9 
and chronic obstructive pulmonary disease (COPD)10, are associated with a more 
M2-like profile. 
Macrophage phenotype is determined in response to molecules that the cells 
interact with in their environment. These include, for example, bacterial components 
(that serve as pathogen-associated molecular patterns or PAMPs), tissue 
components (such as extracellular matrix breakdown products that act as damage-
associated molecular patterns or DAMPs), as well as cytokines, chemokines and 
growth factors (e.g. GM-CSF, IFNβ, IFNγ, IL-4, IL-10, IL-13) released by other cells11–
14. The biological activity of cytokines, chemokines and growth factors in particular is 
highly regulated by their interaction with heparan sulfate (HS) proteoglycans, which 
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are structurally diverse molecules ubiquitously expressed on cell surfaces and in the 
extracellular matrix. HS proteoglycans consist of a core protein that carries one or 
more linear HS polysaccharide chains consisting of alternating N-acetylglucosamine 
(GlcNAc) and hexuronic acid monomers, decorated with variable patterns and levels 
of sulfation15. 
 
Heparan sulfate proteoglycans modulate the activity of inflammatory mediators 
As comprehensively reviewed  by Ori et al.16, HS has been shown to bind to more 
than 400 proteins, including a multitude of chemokines, cytokines and growth factors. 
Several of these are known to affect macrophage activation and behaviour (Fig. 1B) 
and in turn their activity is modulated by binding to HS. Binding of proteins to HS can 
establish gradients (e. g. concentrate them on the cell surface), protect them from 
proteolysis, modulate their bioactivity (e. g. oligomerize chemokines) and affect 
receptor binding17,18. For example, IFNγ, which is critical for polarisation of 
macrophages towards a pro-inflammatory phenotype, binds to HS and this 
interaction inhibits IFNγ binding to its receptor19. Paradoxically, HS binding has been 
shown to increase the activity of IFNγ by promoting its local accumulation and 
inhibiting its rapid proteolytic degradation20. Many other HS binding proteins are also 
likely to or may affect macrophage function, e.g. Indian hedgehog (IHH) promotes 
alternative activation of macrophages21. 
Proteins bind to HS via positively charged amino acid residues (Arg, Lys) that 
interact with the negatively charged sulfate groups on HS22. Changes in HS structure 
change its binding to protein ligands, and consequently affect tissue homeostasis23. 
HS structure is dynamically regulated and has been shown to change with age24–27, 
during development28 and in many pathological contexts29. The structure of HS is 
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thought to be determined by the relative abundance of the 25 different HS 
biosynthetic enzymes (Fig. 230,31), which collectively create a complex sulfation 
pattern that determines affinity for protein ligands32. However, little is known about 
the transcriptional and translational regulation of these HS biosynthetic enzymes. To 
date a systematic examination of how HS biosynthesis is regulated in chronic 
inflammation is lacking, and it is not known whether HS biosynthesis has an impact 
on the development of diseases such as RA. 
 
Macrophage HS is regulated upon polarisation 
Using published microarray data, we analysed expression of HS biosynthetic 
enzymes and core proteins in macrophages upon in vitro polarisation towards an M1 
or an M2 phenotype33–38. This meta-analysis showed that HS sulfotransferase 
expression was largely downregulated in M1 compared to M2 macrophages, for both 
human and murine macrophages (Fig. 3). In line with this change in expression of HS 
biosynthetic enzymes, human M1 macrophages have been shown to contain half the 
amount of HS and have less 2-O and potentially less 3-O sulfation than M2 
macrophages39. However, 3-O sulfation cannot be directly quantified due to the lack 
of commercial standards. 
 
Macrophage HS is regulated in chronic inflammation 
Similarly, we analysed published microarrays examining expression of HS-
associated genes in macrophages isolated from patients with RA40–42 (Fig. 4). This 
revealed that RA macrophages broadly resemble M1 macrophages in terms of HS 
biosynthesis gene expression, in line with studies indicating that RA macrophages 
exhibit an elevated chronic inflammatory state, with increased release of TNF7. In 
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contrast, macrophages from human chronic lung diseases (COPD and asthma) 
exhibited a more M2-like phenotype in terms of the HS biosynthesis gene expression 
profile, in line with reports that M2 macrophages predominate in these diseases43–45.  
Here, we examine the expression of individual HS biosynthesis enzymes and 
core proteins in macrophages upon polarisation, in RA, as well as in other chronic 
inflammatory conditions.  This gives insight as to the contribution of these genes to 
chronic inflammation. 
 
Polymerases 
EXT1 and EXT2 
Exostosin glycosyltransferase 1 (EXT1) and EXT2 act as a heterodimer to synthesise 
the HS backbone by alternating addition of glucuronic acid (GlcA) and GlcNAc to the 
growing HS chain46. They are thus critical for HS biosynthesis, and mutation of either 
enzyme causes hereditary multiple exostoses (HME), characterized by the formation 
of multiple tumors on the lomg bones due to abnormal HS-dependent growth factor 
signalling47. EXT1 has a strong polymerising activity, whereas EXT2 is thought to act 
as a chaperone bringing biosynthetic enzymes to the correct position in the Golgi46. It 
has been hypothesized that EXT1 is the rate-limiting enzyme and that EXT2 is 
normally synthesized in excess48. This is supported by the predominance of EXT1 
mutations in HME and the observation that EXT1 mutations correlate with more 
severe disease than EXT249. A study by Bao et al.50 indicates that EXT expression is 
important in immune responses, as Ext1 deficiency in endothelial cells in mice has 
been shown to impair lymphocyte recruitment in a contact hypersensitivity model due 
to impaired chemokine presentation, but little is known about its role in macrophages.  
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Expression of EXT1 was increased by treatment of human macrophages with 
IFNγ and LPS34, and expression of the enzyme increased 2-fold in in vitro-polarised 
M1 macrophages (Fig. 3)33,34. Increased expression of EXT1 in pro-inflammatory 
environments may imply that HS chain elongation is stimulated by pro-inflammatory 
signals. In support of this, HS chain length is also increased by pro-inflammatory 
cytokines such TNF and decreased by M2-like stimuli such as TGFβ51 in other cell 
types, such as human umbilical endothelial cells (HUVEC). EXT1 expression was 
increased 3-fold in RA macrophages40,41 and also in a murine atherosclerosis 
model52, in line with the more M1-like phenotype of macrophages in these diseases. 
In contrast, EXT1 was largely not regulated in M2-like macrophages from patients 
with chronic lung diseases such as asthma and COPD43,45, and was down-regulated 
in macrophages in murine obesity models53,54. 
On the other hand, EXT2 appeared to be unregulated or decreased by M1 
polarisation33–36 and in RA40. Changes in EXT2 expression may have more limited 
effects on HS structure as EXT2 is normally produced in excess48.  
 
EXTL1-3 
The EXT like (EXTL) family of genes share sequence homology with the EXTs, but 
their role in HS biosynthesis is poorly understood55. EXTL1 is not expressed by 
human macrophages in vitro, while EXTL3 is expressed but not regulated by 
polarisation.  
Among the family, EXTL2 appears to be most regulated in macrophages and its 
expression is dependent on the polarisation protocol. A study in which macrophages 
were polarised in vitro with IFNγ and LPS34 found an increase in EXTL2 expression, 
while studies that used only IFNγ33,36 found downregulation of the gene. This 
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suggests that EXTL2 expression is increased by LPS and decreased by IFNγ. This 
IFNγ polarisation profile mirrors the decrease of EXTL2 in RA40. However, Extl2 
expression was increased in murine models of other M1 chronic inflammatory 
diseases45,52,53,56,57, implying that the regulation of EXTL2 expression is complex.  
Busse et al. hypothesized that EXTL2 initiated HS side chain formation by 
catalysing the addition of the first GlcNAc in the Golgi48, but subsequent studies 
indicated that decreased expression of EXTL2 resulted in longer HS side chains58. 
Nadanaka et al. proposed that the addition of the first GlcNAc to a phosphorylated 
tetrasacharide linker (see ‘Tetrasacharide linker region’ below for more detail) by 
EXTL2 is involved in chain termination and quality control of HS production by 
avoiding over- and abnormal HS production59. It has been demonstrated that EXTL2 
deficiency results in HS overproduction and structural changes, which affected cell 
signalling and liver and blood vessel remodelling upon injury60,61. Further studies are 
required to understand how inflammation changes expression of the EXTL family and 
how this affects HS chain length, amount, quality and ultimately macrophage 
signaling.  
 
N-deacetylase/N-sulfotransferase  
The N-deacetylase/N-sulfotransferase (NDST) family consists of 4 isoforms that 
perform the first HS modification step32. They deacetylate GlcNAc and subsequently 
N-sulfate glucosamine residues. NDST1 and 2 are ubiquitously expressed, while 
NDST3 and 4 are mainly expressed in the brain and fetal tissues62,63, but not in 
macrophages.  
NDST1 and NDST2 are expressed by macrophages and upregulated in human 
IFNγ-polarised M1 macrophages in vitro33,36, indicating a pro-inflammatory role for the 
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NDST enzymes. Other studies reported that inflammatory mediators such as LPS or 
IFNγ+TNF also increase NDST1 and/or NDST2 expression in microvascular 
endothelial cells64,65. NDST1 and NDST2 levels were also increased 1.6-fold in RA 
macrophages40. In contrast, NDST expression is overall not regulated in 
macrophages from patients with more M2-driven diseases, such as asthma43,45. 
 NDST expression seems to be differentially regulated in human and murine 
macrophages. For example, Ndst1 levels decreased in mouse M1 macrophages in 
vitro37 and Ndst1 and Ndst2 were also decreased in murine M1-driven diseases, 
such as cardiovascular disease (CVD)52,57. In line, macrophage-specific inactivation 
of Ndst1 (LysMCre+Ndst1f/f) in mice diminished sulfation and accelerated 
atherosclerosis development and diet-induced obesity. The authors proposed that 
HS proteoglycan sulfation is required for the suppression of basal macrophage 
activation through interferon-β (IFN-β) sequestration66,67, but many other factors that 
bind HS might be involved in the observed phenotype of these mice. In contrast to 
the detrimental effect of Ndst1 deficiency in M1-diseases, deficiency of Ndst1 in the 
endothelium and leukocytes (TekCre+Ndst1f/f) was found to be protective against 
allergen-induced airway remodelling (an M2-driven disease), by reducing the 
recruitment of inflammatory cells and the expression of IL-13, VEGF, TGFβ and FGF-
268. However, from this study it cannot be concluded whether the protective effect 
depends on Ndst1 deficiency in the endothelium or leukocytes. Overall, this indicates 
that the role of NDST enzymes is highly complex and that differences in regulation of 
their expression between mouse and human should be taken into account when 
performing murine studies. 
 
D-Glucuronyl C5-epimerase 
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D-Glucuronyl C5-epimerase (GLCE) converts GlcA to iduronic acid (IdoA) in an 
irreversible reaction that increases the flexibility of the HS chain and so modulates 
ligand binding69,70. GLCE expression was found to be downregulated in human33–36 
and mouse37 M1 macrophages, indicating an anti-inflammatory role for this enzyme. 
In support, GLCE expression was also decreased in RA macrophages40. Currently, 
the functional effects of GLCE in macrophages are unknown. Glce-/- mice displayed 
neonatal lethality with defects in kidney, lung, skeletal development71, lymphoid 
organ development72 and B-cell survival and maturation73. It is highly probable that 
GLCE also affects binding and signalling in macrophages, as all the characterised 
protein binding HS-sites contain at least one IdoA32. 
 
Heparan sulfate sulfotransferases 
Following epimerisation of GlcA into IdoA, one heparan sulfate 2-O sulfotransferase 
(HS2ST1) enzyme can O-sulfate IdoA at the carbon position 2 (Fig. 2). Finally, 3-O 
sulfotransferases (7 isoforms) and 6-O sulfotransferases (3 isoforms) can O-sulfate 
at carbons 3 and 6 of glucosamine30,31. Martinez et al. reported that M1 macrophages 
have decreased 2-O- and 3-O-, but not 6-O-sulfation, as determined by reverse 
phase high-performance liquid chromatography (RP-HPLC) and glycosaminoglycan 
specific antibodies39. The expression of HS2ST1, HS3ST1, HS3ST2 and HS6ST1 is 
dramatically downregulated up to 12.5-fold in human and murine M1 macrophages in 
vitro33–35,37,38, strongly suggesting an anti-inflammatory role of O-sulfation. In line with 
these studies, HS2ST1, HS3ST1, HS3ST2 and HS6ST1 are also decreased up to 
100-fold in macrophages from M1-driven diseases such as RA40,41, while their 
expression is increased in macrophages from more M2-associated diseases, such as 
asthma and COPD43,45.  
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In contrast to the other sulfotransferases, HS3ST3B1 is increased in M1 
polarised macrophages up to 15-fold in vitro34,35, implying an inflammatory role of  
this enzyme. In agreement, HS3ST3B1 is also upregulated 5-fold in RA 
macrophages40, while it is decreased up to 3-fold in macrophages in more M2-driven 
diseases such as COPD43. 
Sulfotransferases are also downregulated in murine M1 macrophages in vitro37, 
but the effects in murine disease models are more heterogenous. Hs3st1 and Hs3st2 
are indeed downregulated in CVD and obesity54,74, while Hs2st1 is slightly increased 
in obesity54 and Hs6st1 is increased in CVD and obesity52–54. This illustrates that 
sulfotransferase expression is also affected by factors other than those (IFNγ, LPS, 
IL-4 and IL-13) which were used for the in vitro studies. This is supported by studies 
showing that TNF (but not IL-4, IL-6 and IFNγ) as well as TLR2 (peptidoglycan) and 
TLR4 (LPS) ligands increase HS3ST3B1 expression in human monocytes75. HS3ST1 
is also upregulated by IL-4+IL-13 in the intestinal epithelium76, whereas HS3ST2 is 
regulated by the circadium rhythm and increased by light77,78 and HS3ST3A1 is 
increased by IL-6 in the canine urothelium79. HS6T1 expression is decreased by 
TGFβ lung fibroblasts80, but not affected by TNF, IFNγ or TGFβ in renal epithelial 
cells81. Conversely, 6-O sulfation in HUVECs is reported to be decreased by 
stimulation with TNF and TGFβ and slightly increased upon IL-1α stimulation51. 
These studies indicate that sulfotransferases are highly regulated by inflammatory 
signals, but a systematic study of their regulation in macrophages and other immune 
cells is lacking. 
 
Modifyers 
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HS can be post-synthetically modified by the extracellular 6-O endosulfatases 
(SULF1 and SULF2) and the endoglycosidase heparanase (HPSE)82.  
 
Sulfatases 
Sulfatases act extracellularly to remove 6-O sulfate groups and so modulate ligand 
binding to HS. Moreover, it has been suggested that SULFs can also translocate to 
the nucleus where they might be involved in cell-cycle regulation83. SULF1 is not 
expressed by macrophages in vitro, while SULF2 is expressed and downregulated 
upon M1 polarisation in vitro of human and murine macrophages33,34,37,38. It is overall 
not regulated in M2-driven diseases such as asthma45. SULF2 appears to be variably 
regulated in M1-associated diseases, as its expression is decreased in obesity54 and 
in one CVD52 study, but increased in RA40 and another CVD57 study. This suggests 
that factors other than IFNγ, LPS, IL-4 and IL-13 affect SULF2 expression in vivo. 
This is supported by studies in other cell types. For example, SULF2 expression is 
increased by TGFβ in renal epithelial cells81, by TNF in nucleus pulposis cells84 and 
by IL-1α in HeLa cells85. Dhoot et al. demonstrated that SULF2 can be expressed as 
an alternatively spliced catalytically inactive variant and found that various tumors 
express this at high levels86–88.  Mechanistically, the inactive variant titrates out the 
active variant and results in an increase in 6-O sulfation and receptor tyrosine kinase 
activation. It would thus also be important to check which splice variants of SULF2 
are expressed in macrophages and other immune cell types during chronic 
inflammation. 
 
Heparanase 
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The heparanase (HPSE) family consists of two isoforms: HPSE1 and HPSE2. 
HPSE1 degrades HS chains by specifically cleaving the bond between GlcA and 
GlcNAc in HS89. Although HPSE2 shares 40% similarity with HSPE1, it is unable to 
cleave HS chains89. HPSE1 expression is increased in various inflammatory 
conditions, such as inflammatory bowel disease (IBD), Crohn’s disease, ulcerative 
colitis and also in the synovial fluid of patients with RA90,91. Inflammatory cytokines 
such as TNF, IFNγ and IL-1β increase HPSE secretion from U937 macrophages and 
endothelial cells92–94. HPSE1 is thought to increase inflammation through three 
different mechanisms. First, inflammation is increased in a positive feedback loop 
since heparanase stimulates pro-inflammatory cytokine secretion from 
macrophages by generating HS oligomers that signal via TLR495. Secondly, 
increased HPSE1 expression might also indirectly enhance inflammation by 
accelerating HS turnover and promoting reshaping of the HS structure. In a tumor 
model, HPSE1 has been shown to increase levels of sulfation and consequently 
augment growth factor signalling96. Finally, HPSE1 might change the free 
concentration of inflammatory mediators in the microenvironment by promoting 
their release from HS89. 
Despite the evidence for an important inflammatory role of HPSE1 in chronic 
diseases, one microarray study showed a decrease in HPSE1 expression in RA 
macrophages40. It is unclear whether macrophage polarisation in vitro affects HPSE1 
expression, as one study on human macrophages reported increased expression33 
upon polarisation with IFNγ, while murine studies reported decreased expression37,38. 
We cannot rule out differences in HPSE1 regulation in mouse and human. In 
addition, HPSE1 expression in other diseases does not correlate with the 
macrophage polarisation state. For example, its expression was decreased in 
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smoking and COPD43,45 and upregulated by oxLDL97 in human studies. In murine 
studies it was decreased in CVD52, but increased in obesity54. It is tempting to 
speculate that feedback mechanisms might be in place to limit the inflammatory 
effects of HSPE1. 
Expression of HPSE2 was also increased in RA40, although its expression is 
undetectable in in vitro-polarised macrophages. Specific environmental cues may 
upregulate HPSE2 in RA. Nevertheless, the functional significance of HPSE2 is 
unknown.  
 
Core proteins 
HS proteoglycan core proteins carry the HS chains, and are also known to have 
biological functions themselves in some cases. They can be grouped into families 
based on their structure and location. The transmembrane syndecans (SDC; 4 
members), the glycosyl phosphoinositol (GPI)-anchored glypicans (GPC; 6 
members) and TGFβ receptor 3 (TGFβR3) are expressed on the cell surface, while 
agrin (AGRN) and perlecan (HSPG2) are present in the extracellular matrix. 
 
Agrin and perlecan 
Perlecan does not appear to be regulated by macrophage polarisation in vitro or by 
chronic inflammation, while AGRN expression is increased 2- to 2.5-fold in 
murine37,38 and human34 macrophages upon M1 polarisation in vitro. Inflammatory 
stimuli, such as IL-1β, have also been shown to increase agrin secretion from other 
cell types51.  
In contrast, AGRN is significantly downregulated in RA (by to 2 fold41) and also 
in other chronic inflammatory conditions (i. e. asthma45, COPD43 and obesity54), but 
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increased in CVD57. Other factors are likely to regulate AGRN expression in these 
contexts, or a negative feedback loop may be responsible for AGRN downregulation. 
Transgenic mice studies indicate that AGRN is vital for macrophage function. Agrn-/- 
mice demonstrate neonatal lethality due to neuromuscular synapse dysfunction98. 
This phenotype can be partially rescued by selective expression of Musk in skeletal 
muscle (Musk-L;Agrn-/-)99. Such mice displayed reduced differentiation and viability of 
monocytes, as well as a reduction in subsequent differentiation into macrophages 
and impaired biological function, with reduced phagocytosis and cytoskeletal 
remodeling99. 
 
Glypicans 
Among the glypicans, expression of GPC3 and GPC4 is regulated in macrophages 
upon chronic inflammation, whereas the other family members are overall not 
affected. For example, GPC3 is downregulated in RA and other chronic inflammatory 
M1- and M2-driven conditions40,45,54,57, but is not differentially regulated by 
macrophage polarisation33–38. Therefore, mediators other than IFNγ, LPS and IL-4 
might be important for GPC3 regulation. GPC3 is likely to be important for the 
generation of macrophages, as Gpc3-/- mice have impaired haematopoiesis of 
monocyte/macrophage progenitors100, while peripheral cell numbers are unaffected. 
In addition, defective hematopoiesis has not been reported in patients with loss of 
function mutations in GPC3, which causes Simpson-Golabi-Behmel Syndrome. It 
could be hypothesized that compensatory mechanisms maintain peripheral cell 
numbers, but it would be interesting to address this during chronic inflammation. 
 In contrast, GPC4 is strongly upregulated by up to 33-fold in RA40,41 and other 
M1-driven conditions such as obesity54. As GPC4 is decreased upon M1 
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macrophage polarisation in vitro33, factors other than IFNγ are likely to be responsible 
for the upregulation of GPC4 during chronic inflammation. GPC4 expression has 
previously been shown to increase in the synovial lining layer and blood vessels in 
RA101, but its function is currently unknown. We speculate that GPC4 contributes to 
inflammation in RA, since GPC4 has been shown to bind and enhance Wnt3a and 
Wnt5a signaling102, which is increased in RA103 and promotes pro-inflammatory 
cytokine release by macrophages (e.g. IL-6 and TNF)104.  However, GPC4 is shed in 
obesity and levels of shed GPC4 correlate with BMI and insulin resistance105. This 
raises the question of whether GPC4 is shed in RA and why GPC4 is not upregulated 
in other chronic inflammatory conditions. 
 
Syndecans 
Sdc1 is expressed at high levels in M2 macrophages and not in M1 macrophages106, 
and is thought to exert an anti-inflammatory effect by sequestering inflammatory 
mediators on its glycan chains107. Additionally, Angsana et al. showed that 
macrophage motility and consequently resolution of inflammation is impaired in Sdc1-
/- mice106.  
 Among the syndecan family, only SDC2 and SDC3 are differentially expressed 
in RA. SDC2 expression was found to increase slightly in RA42, CVD56,74 and 
obesity54 models, but was also increased in M2-driven diseases, such as asthma and 
COPD43–45. Previous studies indicated that macrophages increase SDC2 expression 
upon IL-1α, TNF and LPS treatment108 and IL-1β, IL-6 and TGFβ have also been 
shown to promote SDC2 expression in other cell types109–111. In contrast, SDC2 was 
downregulated in human macrophages upon IFNγ-dependent M1 polarisation in 
vitro33,34,36. 
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SDC2 is also important for the response of macrophages to growth factors and 
cytokines through its core protein. For example, the core protein binds TGFβ, and 
SDC2 upregulates TGFβR expression and enhances its signalling112. Finally, SDC2 
expression is increased in many cancer types, where it is important for cancer cell 
adhesion and migration113. SDC2 may also modulate immune cell adhesion and 
migration. Shedding of SDC2 is also increased by inflammatory signals, such as 
TNF114, potentially via ADAM17 activation115. Such shedding may enable secondary 
downregulation of SDC2 biological activity on the cell surface. Moreover, levels of 
matrix metalloproteinases (MMP) that shed SDC2, such as MMP-7 and MMP-14, are 
elevated in various chronic inflammatory diseases116,117. Systemic study of SDC2 
expression, shedding and function in chronic inflammation is required to better 
understand the contribution of this proteoglycan.  
Little is currently know about the role and regulation of SDC3 in inflammation. In 
contrast to SDC2, SDC3 is downregulated in macrophages from RA40,41 and models 
of M1-driven diseases such as CVD52 and obesity54. SDC3 was upregulated in 
human macrophages by in vitro IFNγ polarisation, but downregulated by IFNγ and 
LPS, suggesting that regulation may be complex. Its biological activity is also likely to 
be complex, as one study demonstrated that SDC3 is pro-inflammatory in the joint, 
but protective in the skin118. 
 
Tetrasaccharide linker region 
Synthesis of HS as well as chondroitin (CS) and closely related dermatan sulfate 
(DS) starts at the tetrasaccharide linker that attaches the sugar chain to the core 
protein (reviewed by Mikami et al.119), so HS biosynthesis in macrophages during 
inflammation might also be regulated at the level of this tetrasacharide linker. 
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Modifications of the linker region determine whether the linker will continue to be 
synthesized as either HS or CS/DS chains and can therefore act as a switch between 
HS or CS/DS synthesis120.  
The tetrasaccharide linker is formed by the action of 4 transferase enzymes, 
namely xylosyltransferase (XYLT1 and XYLT2), β1, 4-galactosyltransferase-I (GalT-
I), β1,3-galactosyltransferase-II (GalT-II) and β1,3-glucoronyltransferase-I (GlcAT-I) 
that sequentially add a xylose, 2 galactose (Gal) and a GlcA residue121. Of these 
enzymes, XYLT1 has been found to be most drastically regulated by macrophage 
polarisation, with a decrease of up to a 20-fold in M1 macrophages 33–36,38 (Fig. 5) 
and a 3-fold decrease in expression in RA macrophages40. This suggests that a 
decrease in linker formation might be an important contributor to the decrease in HS 
content in M1 macrophages observed by Martinez et al.39 However, fibroblasts from 
patients with mutations in XYLT1 produce less CS, but not less HS, suggesting that 
XYLT1 might be more associated with the formation of CS chains122.  
The expression of XYLT2, GalT-I and GalT-II is also downregulated in in vitro 
IFNγ−polarised macrophages36 and macrophages from RA patients40. In contrast, 
expression of these enzymes is increased upon in vitro stimulation with IFNγ in 
combination with LPS 34,37. 
All four of the sugars in the linker region can be modified to regulate the HS-
CS/DS switch. The xylose subunit can be transiently phosphorylated by FAM20B at 
C2. This phosphorylation substantially increases addition of the third and fourth sugar 
units by GalT-II and GlcAT-I, and is thus a prerequisite for the completion of the 
linker region123,124. Once the linker has been synthesised, this xylose residue must be 
dephosphorylated for further HS/CS polymerisation. If this does not occur, EXTL2 
can add a fifth (GlcNac) unit, leading to chain termination60. This series of events is 
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poorly understood. For example, while FAM20B overexpression increases both HS 
and CS synthesis in vitro125, expression of the enzyme was increased in RA40 as well 
as M133,34,38 macrophages, which have lower HS content39. Additionally, the enzyme 
responsible for dephosphorylating the xylose residue is unknown.   
The second and third residues of the linker region can be respectively 6-O, 
and 6-O and 4-O sulfated, with these modifications thought to switch synthesis 
towards CS/DS, but little is known about the enzymes involved118. 
Finally, the fourth sugar (GlcA) can be 3-O-sulfated by human natural killer 1 
sulfotransferase (HNK1ST), promoting chain termination119. Expression of HNK1ST 
is not regulated by macrophage polarisation33-38.  
Several of the enzymes responsible for synthesis of the tetrasaccharide linker 
region are thus regulated by macrophage polarisation and in RA, suggesting they 
may contribute to changes in HS synthesis in acute and chronic inflammation. 
Further investigation is required to evaluate the role(s) of these enzymes and 
whether their expression and activity may be co-ordinately regulated.  
 
Chondroitin and dermatan sulfate 
HS only accounts for 37-45% of the total GAG content in primary human M1 and M2 
macrophages, while CS/DS makes up to 60%-77% of the GAG content in human 
macrophages39 and the murine macrophage cell line J774A.1126. CS/DS differ from 
HS in that their backbone consists of GlcA and GalNAc monomers instead of GlcA 
and GlcNAc, and DS is distinguished from CS by the presence of IdoA instead of 
GlcA119. CS/DS can also be sulfated by various sulfotransferases and while CS 
binding to bioactive proteins is less well studied than for HS, the available data 
suggest that CS can bind to and modulate the activity of mediators in a similar 
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fashion to HS. For example, CS is known to influence Wnt3a signalling127,128. Our 
microarray analysis indicates that all of the CS sulfotransferases are downregulated 
in IFNγ−polarised macrophages33,36 (Fig. 5) and overall that their expression is also 
decreased in RA macrophages40,41. Therefore, it is likely  that changes in CS also 
contribute to altered binding of mediators in acute and chronic inflammation. This 
under-studied area might prove to be important for understanding macrophage 
behaviour during inflammation.  
 
 
Conclusions and future directions 
Macrophage heparan sulfate biosynthesis and core protein expression is dramatically 
affected by polarisation in vitro and upon chronic inflammation, indicating that HS is 
likely to be important for the function of macrophages in inflammation. While there 
are many similarities between HS expression profile in chronic inflammatory diseases 
and following in vitro polarisation, these patterns do not fully mirror each other, 
suggesting that other factors in the microenvironment fine-tune expression of these 
genes. The importance of microenvironment is further supported by studies showing 
that HS expression is not significantly different in in vitro monocyte-derived 
macrophages from the blood of patients with atherosclerosis or systemic lupus 
erythematosus and healthy donors97,129–131. Therefore, to understand the biological 
function of HS in macrophages, it is necessary to study macrophages isolated 
directly from the diseased tissue. Unfortunately, there are currently no published 
datasets with the proper controls to analyse macrophage expression of HS-
associated genes in human atherosclerosis, obesity or IBD. Additionally, differences 
in the macrophage isolation method (e.g. markers for FACS sorting, microdissection) 
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between studies might be partly responsible for the observed differences, since 
purification methods can affect the purity or subset of macrophages analyzed. 
It is difficult to predict how changes in expression of HS biosynthesis enzymes 
will specifically affect HS structure. For example, although M1 macrophages express 
more EXT1 and NDST1/2 than M2 macrophages, they have lower amounts of HS 
and lower HS sulfation. This highlights the importance of validating changes in 
mRNA expression at the protein level, and of analysing effects on HS structure 
directly. Limited availability of good antibodies for HS biosynthetic enzymes can 
make this challenging. Furthermore, Esko and Selleck hypothesized that HS 
biosynthetic enzymes might function as a physical complex, which they termed the 
GAGosome, in which the relative abundance of the biosynthetic enzymes affects 
their function and ultimately HS structure and modification32. Various studies 
demonstrate that changes in the expression of one of the biosynthesis enzymes can 
affect the function of other HS biosynthesis enzymes, which supports the existence 
of the GAGosome32. For example, one study showed that the relative abundance of 
EXT1, EXT2 and NDST1 determine the activity of NDST1132. Overexpression of 
EXT2 increased expression and activity of NDST1, while EXT1 had the opposite 
effect. NDST1 might compete with EXT1 for binding to EXT2 and require EXT2 for 
transport to the Golgi to perform its activity. In another study, inactivation of Hs2st1 
(TieCre+Hs2t1f/f mice) has been shown to not only decrease 2-O sulfation, but also to 
increase N-sulfation and 6-O sulfation and, as a result to alter cytokine and 
chemokine binding133. Moreover, the catalytic activity of HS3ST enzymes has been 
reported to depend on 2-O sulfation134. The complexity of these inter-relationships 
makes it difficult to predict how the changes in expression of HS-associated genes 
shown in Fig. 3 and Fig. 4 impact HS structure. Fig. 6 depicts how we think the 
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changes in expression of HS-associated genes in RA macrophages might affect HS 
structure. Nevertheless, studies directly examining macrophage heparan sulfate 
structure in disease are likely to be challenging, but are clearly required. 
Most of the studies that address functional changes in heparan sulfate gene 
expression in disease focus on the role of one heparan-binding protein, with FGF, 
HGF, PDGF, WNT, VEGF and TGFβ commonly studied. In chronic diseases, it is 
likely that changes in HS structure affect more than one signalling pathway due to the 
heterogeneity and complexity of HS. Immune cells, such as macrophages (Fig. 1B), 
frequently depend on multiple signalling molecules for their function. Therefore, it 
would be beneficial to study differences in the whole macrophage heparan-binding 
proteome in chronic inflammatory diseases in an unbiased way (e.g. by quantitative 
mass spectrometry135). This approach might help to identify potential therapeutic 
targets to treat chronic inflammatory diseases. HS binding of these targets can be 
inhibited using small peptides that resemble their HS-binding site136. This approach 
has been effective for IFNγ and chemokines137,138. 
 Finally, we should be careful in interpreting the effect of macrophage heparan 
sulfate biosynthetic enzymes and core proteins in mouse models of chronic 
inflammatory diseases, since some of the genes (e.g. NDST1) appear to be 
differentially expressed in human and mouse macrophages.  
 In summary, changes in expression of HS core proteins and biosynthetic 
enzymes have the potential to drastically alter signals that macrophages receive and 
therefore to affect their function in chronic inflammation. Systematic investigation of 
how HS changes in chronic inflammation and which signalling pathways this affects 
will broaden our understanding of how macrophage behaviour is regulated in chronic 
inflammation and disease. 
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Figure 1. Several macrophage-modulating bioactive proteins bind to HS.  A. In vitro, 
two extreme activation signatures are defined for macrophages. Interferon-γ (IFNγ) 
and lipopolysaccharide (LPS) or tumor necreosis factor (TNF) are responsible for 
classical activation (previously termed “M1”), which is characterised by nitric oxide 
synthase (iNOS), CD80 and MHC-II expression and secretion of pro-inflammatory 
cytokines. IL-4 and IL-13 result in alternative macrophage activation (previously 
termed “M2”), which is associated with arginase (Arg-1) and mannose receptor (MR, 
or CD206) expression and secretion of IL-10 and TGFβ. In vivo, heterogenous 
activation states are present, depending on stimuli in their local environment5,6. GM-
CSF, various chemokines139 and the complement factors C3a, C5a and C5b-9140 
also promote M1-like differentiation, while immune complexes (IC), IL-10, TGFβ, 
glucocorticoids6, the complement factors C1q and C3b140, tenascin C14, Indian 
hedgehog signalling (IHH)21 and ApoE141 contribute to M2-like activation. Many 
additional factors are also likely to affect macrophage polarisation. B. Many HS-
binding proteins (as reviewed by Ori et al.16) are known to modulate macrophage 
function. In addition to the well-known cytokines and chemokines139, proteins such as 
complement factors can modulate macrophage activation140. MMPs are involved in 
macrophage infiltration142–144 and MMP-7 suppress M1 polarisation, while SHH has 
been shown to act as a macrophage chemoattractant145. 
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Figure 2. Enzymes responsible for heparan sulfate biosynthesis. HS biosynthesis is 
initiated in the Golgi by the formation of a tetrasaccharide linker region (on serine 
residues of the core protein) consisting of a xylose, 2 galactose and a glucuronic acid 
(GlcA) residue. Subsequently, HS chains are synthesized and modified in a template-
independent manner by up to 25 different enzymes. First, the exostosis (EXT) and 
exostosin-like (EXTL) glycosyltransferase enzyme family elongate the HS chain by 
alternating the addition of N-acetyl glucosamine (GlcNAc) and GlcA. Next, the N-
deacetylase/ N-sulfotransferase (NDST) family starts the modification of the HS 
backbone by deacetylating GlcNAc, followed by N-sulfation. Afterwards, glucuronic 
acid epimerase (GLCE) converts some GlcA residues into iduronic acid (IdoA) and a 
2-O-sulfotransferase (HS2ST1) can then sulfate IdoA. Alternatively, glucosamine can 
be sulfated by 6-O-sulfotransferases (HS6ST1-3) and  3-O-sulfotransferases 
(HS3ST1-6). As these enzymes do not completely sulfate the HS chain, they 
generate complex sulfation patterns that form structurally diverse protein-binding 
sites. 6- and 3-O-sulfotransferases are thought to be particularly important, since 
these 10 enzymes have slightly different substrate specificities and are highly 
evolutionarily conserved. Even after HS biosynthesis in the Golgi system, HS can be 
	 47 
extracellularly modified by the endosulfatases SULF1 and SULF2, which can 
specifically remove sulfate groups from the 6-O position. Moreover, heparanase can 
degrade the HS chain into shorter oligosaccharides. Together, these biosynthetic 
enzymes account for the structural diversity of HS30,31.  
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Figure 3. Fold change in the expression of HS biosynthetic enzymes and core 
proteins in in vitro polarised M1 compared to M2 macrophages. Using microarray 
data, we analysed the expression of HS core protein and biosynthetic enzymes upon 
macrophage polarisation in vitro with either IFNγ/LPS (M1) or IL-4/IL-13 (M2). Genes 
marked in dark gray show minimal expression in macrophages in our experience. 
Genes upregulated in M1 compared to M2 macrophages are marked in red (P<0.05) 
or pink (P>0.05), genes downregulated in M1 macrophages are marked in dark blue 
(P<0.05) or light blue (P>0.05) and genes that were not measured are marked with a 
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dash (-). Mehraj33, Martinez F34, Derlindanti35,  Yıldırım-Buharalıoğlu36 compared 
human M1 and M2 macrophages by microarray. Jablonski37 and Jiang38 compared 
M1 and M2 macrophages by microarray from C57BL/6 or BALB/c mice respectively.  
Martinez P39 performed individual qPCRs for NDST’s and sulfotransferases in human 
M1 and M2 macrophages. 
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Figure 4. Fold change in the expression of HS biosynthetic enzymes and core 
proteins in chronic inflammatory diseases. We analysed microarray data on 
expression of HS core protein and biosynthetic enzymes in macrophages isolated 
from chronically inflamed tissues from more M1- (yellow) or M2-associated (green) 
diseases by FACS or laser-capture microdissection. Genes which were increased in 
disease compared to control are marked in red (P<0.05) or pink (P>0.05) and 
downregulated genes are marked in dark blue (P<0.05) or light blue (P>0.05). 
Kang40, Yarilina41 and You42 compared freshly isolated CD14+ cells from human RA 
synovial fluid to CD14+ monocyte-derived macrophages (MDM) from healthy donors. 
Hägg97 compared MDMs isolated from blood of patients with subclinical 
atherosclerosis and a family history of CVD after exposure to oxidised LDL (oxLDL) 
to mimic the atherosclerotic environment with those from healthy donors. Woodruff45, 
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Shaykhiev43 and Kazeros44 compared macrophages isolated from broncheoalveolar 
lavage from smokers, patients with asthma or COPD to those of healthy donors. 
Goo74 compared microdissected macrophages from the aorta of ApoE-/- mice on a 
high fat western-type diet (WTD) for 14 weeks to a normal diet. Feig56 compared 
microdissected macrophages in a progression (Pr) or regression (Re) model of 
atherosclerosis, which promoted M1 or M2 polarisation respectively. Berisha52 
compared bone marrow-derived macrophages (BMDM) from male (M) or female (F) 
atherosclerosis-resistant ApoE-/- AKR mice to BMDM from atherosclerosis-prone 
ApoE-/- DBA/2 mice after loading with acetylated LDL (acLDL). Aurora57 compared 
CD11b+Ly6G- macrophages from the heart of mice 3 days after experimental 
myocardial infarction at postnatal day 14 (P14; non-regenerating) to P1 
(regenerating). Xu53 compared CD11c+ and CD11c- (generally considered to 
represent M1 and M2 macrophages) CD11b+F480+ macrophages from the 
perigonodal cells of leptin-deficient obese mice to wild-type mice. Although HS-
associated genes were differentially expressed upon obesity in CD11c+ 
macrophages, no differences were observed in CD11c- macrophages. Prieur54 
compared CD11b+ macrophages from gonadal white adipose tissue of leptin-
deficient obese mice after 5 (5W) or 16 weeks (16W) of WTD to wild-type mice. They 
demonstrated that macrophages have a more M2-like phenotype after 5 weeks and 
more M1-like after 16 weeks of diet. 
  
	 52 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Fold change in the expression of enzymes involved in the formation of the 
tetrasaccharide linker and CS biosynthetic enzymes and core proteins upon 
macrophage polarisation and RA. Using microarray data, we analysed the 
expression of HS core protein and biosynthetic enzymes upon macrophage 
polarisation in vitro with either IFNγ/LPS (M1) or IL-4/IL-13 (M2) or in rheumatoid 
arthritis (RA). Genes marked in dark gray show minimal expression in macrophages 
in our experience. Genes upregulated in M1/ RA compared to M2/ healthy 
macrophages are marked in red (P<0.05) or pink (P>0.05), genes downregulated in 
M1/ RA macrophages are marked in dark blue (P<0.05) or light blue (P>0.05) and 
genes that were not measured are marked with a dash (-). Mehraj33, Martinez F34, 
Derlindanti35,  Yıldırım-Buharalıoğlu36 compared human M1 and M2 macrophages by 
microarray. Jablonski37 and Jiang38 compared M1 and M2 macrophages by 
microarray from C57BL/6 or BALB/c mice respectively.  Martinez P39 performed 
individual qPCRs for NDST’s and sulfotransferases in human M1 and M2 
macrophages. Kang40, Yarilina41 and You42 compared CD14+ cells freshly isolated 
by FACS from human RA synovial fluid to CD14+ monocyte-derived macrophages 
(MDM) from healthy donors. 
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Figure 6. Schematic summary of changes in HS biosynthesis in macrophages from 
RA patients. Analysis of microarray studies demonstrated that macrophages from RA 
synovial fluid express more glypican-4. As EXT1 was also increased, we hypothesize 
that the HS chain length is increased in RA. NDST expression was also increased, 
suggesting increased N-sulfation, while decreased GLCE and 2-O sulfotransferase 
expression suggest decreased epimerisation and 2-O sulfation. Decreased 6-O 
sulfatase expression combined with an increase in SULF2 point to a net decrease in 
6-O sulfation. The pattern of 3-O sulfation might also be altered, as the HS3ST1 and 
2 isoforms are decreased, while HS3ST3B1 was increased. Nevertheless, 
expression data alone cannot be used to predict HS structure and studies directly 
studying HS structure are required. Abbreviations: GlcA,  glucuronic acid; IdoA, 
iduronic acid; GlcNAc , N-acetyl glucosamine; GlcNS, N-sulfated glucuronic acid; NS, 
N-sulfation;  2S, 2-O sulfation; 3S, 3-O sulfation; 6S, 6-O sulfation. 
 
